The Food and Drug Administration (FDA) has announced that a priority review voucher has been issued to Ridgeback Biotherapeutics, LP, for their product EBANGA. This product, approved on December 21, 2020, is used to treat infections caused by the Zaire ebolavirus. The priority review voucher is part of a program authorized by the Federal Food, Drug, and Cosmetic Act to expedite review processes for material threat medical countermeasures. More information about this program and product can be found on the FDA's website.
Simple Explanation
The FDA gave a special "fast pass" to a company that makes a medicine called EBANGA, which helps treat a really bad virus, so they can get quicker approval for another important medicine in the future.